X0306 4 2015-11-02 1 0000802724 INSITE VISION INC INSV 0001430587 Hosseini Kamran 965 ATLANTIC AVENUE ALAMEDA CA 94501 0 1 0 0 VP, Clinical Affairs & CMO Stock Option (right to buy) 0.60 2015-11-02 4 D 0 40000 D 2009-03-24 2018-03-24 Common Stock 40000 0 D Stock Option (right to buy) 0.20 2015-11-02 4 D 0 300000 0.35 D 2010-02-17 2019-02-17 Common Stock 300000 0 D Stock Option (right to buy) 0.42 2015-11-02 4 D 0 300000 D 2011-04-01 2020-04-01 Common Stock 300000 0 D Stock Option (right to buy) 0.36 2015-11-02 4 D 0 250000 D 2012-01-21 2021-01-21 Common Stock 250000 0 D Stock Option (right to buy) 0.50 2015-11-02 4 D 0 250000 D 2013-01-27 2022-01-27 Common Stock 250000 0 D Stock Option (right to buy) 0.32 2015-11-02 4 D 0 325000 0.35 D 2014-01-24 2023-01-24 Common Stock 325000 0 D Stock Option (right to buy) 0.29 2015-11-02 4 D 0 325000 0.35 D 2015-01-07 2024-01-07 Common Stock 325000 0 D Stock Option (right to buy) 0.21 2015-11-02 4 D 0 325000 0.35 D 2016-01-28 2025-01-28 Common Stock 325000 0 D The option is scheduled to vest as to 25% of the shares covered by the option on the first anniversary of the grant date and as to the remaining 75% of the shares on a daily basis over the three-year period thereafter. In accordance with the terms of the Agreement and Plan of Merger, dated September 15, 2015, as amended and restated, by and among Thea Acquisition Corp ("Purchaser"), Ranbaxy, Inc. and InSite Vision Incorporated ("Issuer") pursuant to which Purchaser was merged with and into Issuer (the "Merger"), this stock option was cancelled at the effective time of the Merger without consideration because the exercise price of the stock option equaled or exceeded $0.35 per share. This option was cancelled in connection with the Merger in exchange for a cash payment per share equal to the difference between $0.35 and the exercise price of the option. /s/ Kamran Hosseini 2015-11-04